P atients deserve to be medically optimised for treatment of metabolic risk factors and hypertension before referral for elective coronary artery bypass grafting (CABG). We describe here a prospective study of 347 consecutive patients referred for elective CABG. An oral glucose tolerance test (OGTT) was performed and metabolic risk factors and hypertension were determined pre-operatively. Compliance to treatment guidelines was calculated.
Introduction
Several studies have shown that acute coronary syndrome patients have a high incidence of previously undiagnosed diabetes mellitus, which may be partly explained by the fact that many of these acute patients have had limited previous contact with medical care providers. 1, 2 An earlier study suggested that there is a high incidence of undiagnosed diabetes and pre-diabetes even among patients who have had extensive contacts with primary care and with cardiologists who have referred them for elective coronary artery bypass grafting (CABG). 3, 4 Furthermore, patients with pre-diabetes share with patients with known diabetes the same increased risk for early mortality after CABG. 3 The European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD) have recently updated their guidelines for diagnosis and treatment of risk factors for patients with cardiovascular disease, paying particular attention to patients with diabetes and pre-diabetes. 5 Dysglycaemia is now recognised as a risk continuum, and an oral glucose tolerance test (OGTT) is recommended for all patients with cardiovascular disease. 5 It is unknown how often elective patients, who have seen both general practitioners and at least one cardiologist, have had their metabolic risk factors and blood pressure diagnosed and treated according to guideline recommendations.
As glucose intolerance has been shown to correlate even better than fasting blood glucose with cardiovascular disease, we chose in the present study to examine among patients referred for elective CABG surgery, the true incidence of diabetes and pre-diabetes and the adequacy of their risk factor treatment just prior to surgery. [5] [6] [7] [8] Methods Consecutive patients (n=347) scheduled for elective CABG surgery underwent an admission procedure 1-2 weeks before surgery at our outpatient clinic. All cardiac surgery in Sweden is performed at one of seven regional hospitals. After ethical permission had been granted, a test programme was initiated. Blood samples were drawn upon arrival in all patients for fasting plasma glucose (fP-Glu), per cent glycosylated haemoglobin (HbA 1C ; Swedish MonoS standardised method with normal = 3.6-5.3%, equivalent to 4.6-6.3% DCCT-calibrated), low-density lipoprotein/high-density lipoprotein (LDL/HDL)-cholesterol and triglycerides. This
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Only a minority of patients referred for elective coronary artery bypass surgery have risk factors diagnosed and treated according to established guidelines was followed by an oral glucose tolerance test (OGTT=75 g glucose in 2 dL water) for patients not having previously diagnosed diabetes. Plasma glucose (P-Glu) was tested after 120 minutes (Hemocue 201+ P-Glucose System; HemoCue AB, Ängelholm, Sweden; r=0.998 for glucose measured with Hemocue versus isotope dilution gas chromatography-mass spectrometry). Resting blood pressure, weight, height and waist circumference were measured. Patients' medications, history of myocardial infarction and associated diagnoses were recorded. A second fP-Glu was sampled early in the morning of the day of surgery.
Definitions
Diabetes mellitus was defined as either P-Glu > 11.1 mmol/L at two hours after OGTT or fP-Glu > 7.0 mmol/L on two separate days. 5 Pre-diabetes is defined as either glucose intolerance (7.8 < P-Glu < 11.1 mmol/L at two hours after OGTT) and/or impaired fasting glucose (5.6 < fP-Glu < 7.0 mmol/L using the more recent definition by the American Diabetes Association rather than that of the World Health Organization [WHO].) 5 Dysglycaemia denotes both diabetes and prediabetes. 5 Body mass index (BMI) was calculated by dividing weight in kilograms by the square of the height in metres. Risk factor guidelines in Sweden for treating patients with cardiovascular disease are the same as those established by the European Society of Cardiology and the American Heart and Diabetes Associations. 5, 6, 9 Guidelines (shown in table 1) are well known throughout the highly homogenous medical care system in Sweden. Recommendations include:
Additionally, they recommend statin treatment irrespective of cholesterol levels and a renin-angiotensin-aldosterone system inhibitor for patients with diabetes. An OGTT is recommended in all patients with cardiovascular disease.
Results
Of all 347 patients included, 73 (21%) had normal glucose tolerance and at least one normal fP-Glu. Of these 73 patients, 17 (23%) had moderately increased HbA 1C (5-7%, table 1). Almost as many patients had previously unknown (66 patients or 19%) as previously known (80 patients or 23%) diabetes, and 128 (37%) of patients had pre-diabetes (figure 1). Of the patients without previously known diabetes, 66 (24%) had manifest diabetes and 128 (48%) had pre-diabetes. A diagnosis of diabetes was established for three times as many patients with OGTT as would have been the case with two fP-Glu measurements on two different days. fP-Glu diagnosed diabetes in only one patient who had a normal OGTT and in five patients who had impaired glucose tolerance. Glucose levels two hours post-OGTT and both fP-Glu (average of two values) and HbA 1C were correlated (r=0.62).
There was a stepwise increase of BMI and waist circumference among patients with normoglycaemia, pre-diabetes, new diabetes and known diabetes (table 1). Almost 80% of patients were male. A history of previous myocardial infarction and treatment for hypertension was common.
Only a minority of patients with dysglycaemia met guideline levels for effective treatment of hyperlipidaemia, such as 43/274 (16%) for LDL-cholesterol, although 206 (75%) were being treated with statins ( figure 2 ). Of patients with known and unknown diabetes taking statins, 84% and 81% were on simvastatin with an average dose of 21 mg and 27 mg, respectively. One percent of patients were taking combination therapy with ezetimibe.
Blood pressure guideline goals were achieved in 39/274 (14%) of dysglycaemic patients. Among patients with dysglycaemia, 111/274 (41%) took one antihypertensive agent or none. Renin-angiotensin-aldosterone system inhibitors had been prescribed for 79 (54%) of the patients with previously undiagnosed diabetes or pre-diabetes.
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least one family doctor and one cardiologist, almost half of the patients with manifest diabetes had not been diagnosed before referral for elective CABG. Guideline target values for blood pressure and blood lipids were achieved in only a minority of patients, with consistent underuse of statins and renin-angiotensin-aldosterone system inhibitors. 5, 9, 10 Undetected diabetes and pre-diabetes has several negative consequences. Most obvious is prolonged, unmedicated hyperglycaemia. Secondly, many patients will be incorrectly placed in a lower-risk group and will be treated less aggressively for other risk factors, as recommended for patients with diabetes. 4, 8, 9 Thirdly, patients with pre-diabetes will be deprived of the possibility of preventing, or at least delaying, progression of their pre-diabetes to clinical diabetes; both lifestyle changes and medications have a major impact on progression of insulin resistance. 5 Finally, the hazard ratio for dysglycaemia in conjunction with CABG will be underestimated.
The increase in risk associated with dysglycaemia is grossly underestimated in the literature: when mortality is calculated for patients undergoing CABG, for example, those with known diabetes are compared with all those patients who are assumed to be without diabetes. The so-called non-diabetic group will have an incorrectly exaggerated mortality as the majority of individuals in this group have either undiagnosed diabetes or pre-diabetes. Both the study by Muhlestein et al. of patients undergoing angioplasty/stenting and our study with CABG patients have shown that mortality is increased as much for patients with pre-diabetes as for those with manifest diabetes. 3, 11 By regrouping data in these two studies to compare only patients found to have normoglycaemia with all those found to have diabetes or pre-diabetes, it can be shown that early mortality after CABG surgery is reduced for truly normoglycaemic patients while for those with dysglycaemia mortality is increased by more than 150%. 3 Similarly, recalculating data for percutaneous coronary intervention (PCI) patients more than doubles the true increase in risk associated with dysglycaemia. 11 Fasting glucose concentrations used in the studies cited above underestimate the incidence of diabetes as glucose intolerance often precedes increased fasting glucose. 5, 8 In patients studied here, both fasting glucose and HbA 1C correlated well with the two-hour glucose response to OGTT, and while fasting glucose identified a few patients with diabetes when OGTT did not, HbA 1C did not help in screening. Furthermore, impaired glucose tolerance has been shown to correlate better than fasting glucose with cardiovascular complications. [5] [6] [7] [8] 12 Postprandial hyperglycaemia is now believed to be the dominant factor in diabetes complications and has even been shown to reduce myocardial perfusion transiently. 8, 13 In the present study diabetes was diagnosed three times more often with OGTT than with fasting glucose tested on two different days. OGTT is a trivial procedure using only the two-hour glucose concentration, it is easily implemented at any outpatient clinic, and it is recommended by the European Society of Cardiology for all patients with cardiovascular disease. 5 The literature contains plentiful studies demonstrating the need for diagnosis of diabetes and aggressive treatment of the associated risk factors. Steno-2, for example, showed a 50% decreased mortality/morbidity with aggressive versus conventional treatment. 14 A recent study from Framingham has shown a linear relationship between blood glucose and cardiovascular mortality down to 3.5 mmol/L. 15 Studies show that patients with diabetes should receive renin-angiotensinaldosterone system inhibitors but these drugs were not being taken by more than half of the patients in the present study. 5, 16 Several studies have shown that these drugs reduce conversion to manifest diabetes, although a reduction was not seen in patients without cardiovascular disease in the recent Diabetes REduction Approaches with ramipril and rosiglitazone Medication (DREAM) study with ramipril. 16, 17 "Lower is better" applies to LDL-cholesterol, as shown by the benefits for patients with diabetes with LDL-cholesterol reduction below 1.8 mmol/L, reflected in the new guidelines recommending treatment to below this level. 5, 10, 18 In our patients, this target was achieved in fewer than one in five patients with diabetes. High-dose statins before CABG surgery, and before PCI, have been shown to improve prognosis but statins were given to only three fourths of the patients referred for surgery in the present study, and even then at very low doses. 19 Statins, particularly at higher doses, reduce mortality from acute myocardial infarctions and are beneficial even for patients with normal levels of LDL-cholesterol, with no apparent increase in adverse effects with higher doses. 16, [20] [21] [22] [23] While statins may not decrease the incidence of perioperative myocardial infarctions and stroke, their beneficial effects on these acute events in a non-surgical setting may also apply to these complications of cardiac surgery. Pre-operative statin treatment is associated with lower early mortality after CABG, while discontinuation of statin treatment after surgery is associated with increased mortality. 24 Blood pressure below 130/80 mmHg is recommended for patients with diabetes and other high-risk patients. 5 This recommended level was achieved in very few patients with diabetes, and few antihypertensive medications were used. Ongoing post hoc analysis of the Treating to New Targets study suggest that hypertension risk reduction is linear, with "lower is better" applying to blood pressure as well as to blood lipids. 18 One limitation of this study is that there may be regional and national variations in risk factor treatment. Sweden has a well organised universal healthcare system, with uniform national treatment guidelines virtually identical to those of both European and American guidelines. All patients requiring CABG are referred to the nearest of the seven stateowned cardiothoracic surgical centres. There is little reason to suspect that this study's findings differ significantly from those of most other European centres. Similar undertreatment has been demonstrated before but not in patients with cardiovascular pathology so advanced that they require elective referral for CABG. 25 A second limitation is the exclusion of acute patients due to lack of time, as these patients are often not fasting and may have stress-induced hyperglycaemia. As many acute patients have had limited previous contact with medical caregivers, their risk factor treatment is likely to be even worse than for elective patients. Compliance was not studied, only patients' prescribed medications. Finally, this study is of course underpowered for studying mortality.
Titration of risk factor treatment to guideline targets seems to be uncommon, even in elective CABG patients. CABG is a scheduled procedure in a high-risk population for whom there is generally ample time for optimisation of risk factor diagnosis and titration of treatment to established guidelines. Failure to diagnose dysglycaemia pre-operatively in patients referred for elective CABG contributes to inadequate risk factor treatment in a majority of referred patients, which may result in an unnecessary reduction in post-operative survival. Hospital admission for a cardiac procedure is an opportunity to identify large numbers of patients who will benefit the most from aggressive risk factor control.
